Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPS804 multiple infusion dose-escalation in adults with hypophosphatasia
2010-024013-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setrusumab in hypophosphatasia (HPP), sponsored by Novartis. Primary endpoint: Safety and tolerability of multiple infusions of BPS804. Started Feb 2011; status: completed.
02
Drugs
setrusumab
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2010-024013-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024013-31.